SCHEMBL3606786

SCHEMBL3606786

COc1ccccc1N1CCN(CCCCOc2cccc3c(C=O)cnn23)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 11/20 0.73
DRD2 P14416 10/20 0.73
DRD3 P35462 10/20 0.73
HTR2A P28223 10/20 0.68
DRD1 P21728 8/20 0.68
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
HTR1A P08908 3/20 0.54
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
LMNA P02545 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MAPT P10636 1/20 0.52
NLRP1 Q9C000 1/20 0.52
HTR7 P34969 2/20 0.51
SLC6A2 P23975 1/20 0.51
SLC6A4 P31645 1/20 0.51
ADRA2A P08913 1/20 0.51
ADRA2B P18089 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614804 0.88 DRD3 (0.89) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL3612107 0.84 DRD2 (1.00) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL3615512 0.81 DRD2 (1.00) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL3615975 0.80 DRD2 (1.00) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL3612294 0.80 DRD2 (0.74) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL3618867 0.79 DRD2 (0.93) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL3608995 0.79 DRD2 (0.70) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL3609757 0.73 DRD2 (0.73) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL4441972 0.73 DRD2 (0.83) DRD4DRD2DRD3HTR2ADRD1
SCHEMBL6526368 0.71 DRD2 (0.85) DRD2DRD3HTR2AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168125-A1 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS DONSBACH, MARTIN (DE) 2010-07-01 US claimed
EP-2137185-A2 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS Gmeiner, Dr. Peter (DE) 2009-12-30 EP claimed
WO-2008113559-A2 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS SCHWARZ PHARMA AG (DE) 2008-09-25 WO claimed
EP-1972628-A1 Indolizines and aza-analog derivatives thereof as CNS active compounds SCHWARZ PHARMA AG (DE) 2008-09-24 EP claimed
US-20100168125-A1 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS DONSBACH, MARTIN (DE) 2010-07-01 US disclosed
EP-2137185-A2 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS Gmeiner, Dr. Peter (DE) 2009-12-30 EP disclosed
WO-2008113559-A2 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS SCHWARZ PHARMA AG (DE) 2008-09-25 WO disclosed
EP-1972628-A1 Indolizines and aza-analog derivatives thereof as CNS active compounds SCHWARZ PHARMA AG (DE) 2008-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168125-A1 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS INMT, AANAT, AZI2 DRD4 133/4885DRD2 123/4885DRD3 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.